Comparative Pharmacology
Head-to-head clinical analysis: DACARBAZINE versus MUSTARGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DACARBAZINE versus MUSTARGEN.
DACARBAZINE vs MUSTARGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alkylating agent; inhibits DNA and RNA synthesis by forming covalent bonds with DNA, leading to cross-linking and strand breaks. Also inhibits purine synthesis and has some activity as a methylating agent.
MUSTARGEN (mechlorethamine HCl) is a nitrogen mustard alkylating agent that forms cross-links between DNA strands, inhibiting DNA replication and transcription, leading to cell death.
2.4-4.5 mg/kg IV daily for 10 days every 28 days; or 250 mg/m2 IV daily for 5 days every 21 days; or 375-450 mg/m2 IV single dose every 21-28 days.
IV: 0.4 mg/kg or 12 mg/m² BSA as a single dose or divided into 0.1 mg/kg/day for 4 days.
None Documented
None Documented
Clinical Note
moderateDacarbazine + Digoxin
"Dacarbazine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDacarbazine + Digitoxin
"Dacarbazine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDacarbazine + Deslanoside
"Dacarbazine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDacarbazine + Acetyldigitoxin
"Dacarbazine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life: 5 hours (range 3-8 h) after IV administration; biphasic decay with initial half-life ~19 min.
Terminal half-life: 30-60 minutes (rapidly inactivated); clinical context: very short due to rapid hydrolysis and alkylation, necessitating rapid administration after reconstitution.
Renal: 40-50% unchanged; hepatic: 30-50% as metabolites (primarily 5-aminoimidazole-4-carboxamide); <10% fecal.
Renal: 50% as unchanged drug and metabolites; fecal: minor (<10%); biliary: minimal.
Category D/X
Category C
Alkylating Agent
Alkylating Agent